{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T14:05:08Z","timestamp":1777039508030,"version":"3.51.4"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2019,9,3]],"date-time":"2019-09-03T00:00:00Z","timestamp":1567468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,9,3]],"date-time":"2019-09-03T00:00:00Z","timestamp":1567468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005788","name":"Medical University of Vienna","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s00417-019-04444-6","type":"journal-article","created":{"date-parts":[[2019,9,3]],"date-time":"2019-09-03T10:04:57Z","timestamp":1567505097000},"page":"2751-2757","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Visual function in chronic Leber\u2019s hereditary optic neuropathy during idebenone treatment initiated 5 to 50\u00a0years after onset"],"prefix":"10.1007","volume":"257","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0569-0229","authenticated-orcid":false,"given":"Berthold","family":"Pemp","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karl","family":"Kircher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Reitner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,9,3]]},"reference":[{"key":"4444_CR1","doi-asserted-by":"publisher","first-page":"461","DOI":"10.5301\/ejo.5000055","volume":"22","author":"B Mascialino","year":"2012","unstructured":"Mascialino B, Leinonen M, Meier T (2012) Meta-analysis of the prevalence of Leber hereditary optic neuropathy mtDNA mutations in Europe. Eur J Ophthalmol 22:461\u2013465","journal-title":"Eur J Ophthalmol"},{"key":"4444_CR2","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1136\/jmg.2007.054270","volume":"46","author":"P Yu-Wai-Man","year":"2009","unstructured":"Yu-Wai-Man P, Griffiths PG, Hudson G, Chinnery PF (2009) Inherited mitochondrial optic neuropathies. J Med Genet 46:145\u2013158","journal-title":"J Med Genet"},{"key":"4444_CR3","doi-asserted-by":"publisher","first-page":"3112","DOI":"10.1167\/iovs.08-3166","volume":"50","author":"MA Kirkman","year":"2009","unstructured":"Kirkman MA, Korsten A, Leonhardt M, Dimitriadis K, De Coo IF, Klopstock T, Griffiths PG, Hudson G, Chinnery PF, Yu-Wai-Man P (2009) Quality of life in patients with Leber hereditary optic neuropathy. Invest Ophthalmol Vis Sci 50:3112\u20133115","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"4444_CR4","first-page":"266","volume":"4","author":"A von Graefe","year":"1858","unstructured":"von Graefe A (1858) Ein ungew\u00f6hnlicher Fall yon herediti\u00e4rer Amaurose. Arch Ophthalmol 4:266\u2013268","journal-title":"Arch Ophthalmol"},{"key":"4444_CR5","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/BF01694557","volume":"17","author":"T Leber","year":"1871","unstructured":"Leber T (1871) Ueber heredit\u00e4re und congenital-angelegte Sehnervenleiden. Graefes Arch Ophthalmol 17:249\u2013291","journal-title":"Graefes Arch Ophthalmol"},{"key":"4444_CR6","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1146\/annurev-vision-082114-035651","volume":"1","author":"JL Wiggs","year":"2015","unstructured":"Wiggs JL (2015) Mitochondrial genetics and optic neuropathy. Annu Rev Vis Sci 1:97\u2013124","journal-title":"Annu Rev Vis Sci"},{"key":"4444_CR7","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1093\/brain\/awr170","volume":"134","author":"T Klopstock","year":"2011","unstructured":"Klopstock T, Yu-Wai-Man P, Dimitriadis K, Rouleau J, Heck S, Bailie M, Atawan A, Chattopadhyay S, Schubert M, Garip A, Kernt M, Petraki D, Rummey C, Leinonen M, Metz G, Griffiths PG, Meier T, Chinnery PF (2011) A randomized placebo-controlled trial of idebenone in Leber\u2019s hereditary optic neuropathy. Brain 134:2677\u20132686","journal-title":"Brain"},{"key":"4444_CR8","doi-asserted-by":"publisher","first-page":"e188","DOI":"10.1093\/brain\/awr180","volume":"134","author":"V Carelli","year":"2011","unstructured":"Carelli V, La Morgia C, Valentino ML, Rizzo G, Carbonelli M, De Negri AM, Sadun F, Carta A, Guerriero S, Simonelli F, Sadun AA, Aggarwal D, Liguori R, Avoni P, Baruzzi A, Zeviani M, Montagna P, Barboni P (2011) Idebenone treatment in Leber\u2019s hereditary optic neuropathy. Brain 134:e188","journal-title":"Brain"},{"key":"4444_CR9","unstructured":"European Medicines Agency (2015) Assessment report Raxone. \nhttps:\/\/www.ema.europa.eu\/documents\/assessment-report\/raxone-epar-public-assessment-report_en.pdf\n\n. Accessed 12 June 2019"},{"key":"4444_CR10","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1097\/WNO.0000000000000570","volume":"37","author":"V Carelli","year":"2017","unstructured":"Carelli V, Carbonelli M, de Coo IF, Kawasaki A, Klopstock T, Lagr\u00e8ze WA, La Morgia C, Newman NJ, Orssaud C, Pott JWR, Sadun AA, van Everdingen J, Vignal-Clermont C, Votruba M, Yu-Wai-Man P, Barboni P (2017) International consensus statement on the clinical and therapeutic management of Leber hereditary optic neuropathy. J Neuroophthalmol 37:371\u2013381","journal-title":"J Neuroophthalmol"},{"key":"4444_CR11","unstructured":"World Health Organization (2016) International Statistical Classification of Diseases and Related Health Problems 10th Revision, Version 2016. \nhttps:\/\/icd.who.int\/browse10\/2016\/en#\/H54.0\n\n. Accessed 12 June 2019"},{"issue":"supplement 4","key":"4444_CR12","first-page":"A4","volume":"50","author":"V Carelli","year":"1998","unstructured":"Carelli V, Ghelli A, Cevoli S, Cortelli P, Lugaresi E, Baruzzi A, Leuzzi V, Degli Esposti M, Barboni P, Montagna P (1998) Idebenone therapy in Leber\u2019s hereditary optic neuropathy: report of six cases. Neurology 50(supplement 4):A4","journal-title":"Neurology"},{"key":"4444_CR13","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.ajo.2005.11.007","volume":"141","author":"L Spruijt","year":"2006","unstructured":"Spruijt L, Kolbach DN, de Coo RF, Plomp AS, Bauer NJ, Smeets HJ, de Die-Smulders CE (2006) Influence of mutation type on clinical expression of Leber hereditary optic neuropathy. Am J Ophthalmol 141:676\u2013682","journal-title":"Am J Ophthalmol"},{"key":"4444_CR14","first-page":"10","volume":"12","author":"EM Stone","year":"1992","unstructured":"Stone EM, Newman NJ, Miller NR, Johns DR, Lott MT, Wallace DC (1992) Visual recovery in patients with Leber\u2019s hereditary optic neuropathy and the 11778 mutation. J Clin Neuroophthalmol 12:10\u201314","journal-title":"J Clin Neuroophthalmol"},{"key":"4444_CR15","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1093\/brain\/118.2.319","volume":"118","author":"P Riordan-Eva","year":"1995","unstructured":"Riordan-Eva P, Sanders MD, Govan GG, Sweeney MG, Da Costa J, Harding AE (1995) The clinical features of Leber\u2019s hereditary optic neuropathy defined by the presence of a pathogenic mitochondrial DNA mutation. Brain 118:319\u2013337","journal-title":"Brain"},{"key":"4444_CR16","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.preteyeres.2018.04.001","volume":"65","author":"LE Fry","year":"2018","unstructured":"Fry LE, Fahy E, Chrysostomou V, Hui F, Tang J, van Wijngaarden P, Petrou S, Crowston JG (2018) The coma in glaucoma: retinal ganglion cell dysfunction and recovery. Prog Retin Eye Res 65:77\u201392","journal-title":"Prog Retin Eye Res"},{"key":"4444_CR17","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.mcn.2012.08.004","volume":"55","author":"A Maresca","year":"2013","unstructured":"Maresca A, la Morgia C, Caporali L, Valentino ML, Carelli V (2013) The optic nerve: a \u201cmito-window\u201d on mitochondrial neurodegeneration. Mol Cell Neurosci 55:62\u201376","journal-title":"Mol Cell Neurosci"},{"key":"4444_CR18","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1016\/S0042-6989(97)00444-6","volume":"38","author":"N Howell","year":"1998","unstructured":"Howell N (1998) Leber hereditary optic neuropathy: respiratory chain dysfunction and degeneration of the optic nerve. Vis Res 38:1495\u20131504","journal-title":"Vis Res"},{"key":"4444_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0022-510X(99)00087-8","volume":"165","author":"MD Brown","year":"1999","unstructured":"Brown MD (1999) The enigmatic relationship between mitochondrial dysfunction and Leber\u2019s hereditary optic neuropathy. J Neurol Sci 165:1\u20135","journal-title":"J Neurol Sci"},{"key":"4444_CR20","doi-asserted-by":"publisher","first-page":"39831","DOI":"10.1074\/jbc.M006476200","volume":"275","author":"MD Brown","year":"2000","unstructured":"Brown MD, Trounce IA, Jun AS, Allen JC, Wallace DC (2000) Functional analysis of lymphoblast and cybrid mitochondria containing the 3460, 11778, or 14484 Leber\u2019s hereditary optic neuropathy mitochondrial DNA mutation. J Biol Chem 275:39831\u201339836","journal-title":"J Biol Chem"},{"key":"4444_CR21","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1136\/jnnp.70.3.359","volume":"70","author":"P Klivenyi","year":"2001","unstructured":"Klivenyi P, Karg E, Rozsa C, Horvath R, Komoly S, Nemeth I, Turi S, Vecsei L (2001) Alpha-tocopherol\/lipid ratio in blood is decreased in patients with Leber\u2019s hereditary optic neuropathy and asymptomatic carriers of the 11778 mtDNA mutation. J Neurol Neurosurg Psychiatry 70:359\u2013362","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"4444_CR22","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.bbabio.2004.05.009","volume":"1658","author":"V Carelli","year":"2004","unstructured":"Carelli V, Rugolo M, Sgarbi G, Ghelli A, Zanna C, Baracca A, Lenaz G, Napoli E, Martinuzzi A, Solaini G (2004) Bioenergetics shapes cellular death pathways in Leber\u2019s hereditary optic neuropathy: a model of mitochondrial neurodegeneration. Biochim Biophys Acta 1658:172\u2013179","journal-title":"Biochim Biophys Acta"},{"key":"4444_CR23","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1001\/archneur.62.5.730","volume":"62","author":"A Baracca","year":"2005","unstructured":"Baracca A, Solaini G, Sgarbi G, Lenaz G, Baruzzi A, Schapira AH, Martinuzzi A, Carelli V (2005) Severe impairment of complex I-driven adenosine triphosphate synthesis in leber hereditary optic neuropathy cybrids. Arch Neurol 62:730\u2013736","journal-title":"Arch Neurol"},{"key":"4444_CR24","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1212\/WNL.0000000000002688","volume":"86","author":"E Dombi","year":"2016","unstructured":"Dombi E, Diot A, Morten K, Carver J, Lodge T, Fratter C, Ng YS, Liao C, Muir R, Blakely EL, Hargreaves I, Al-Dosary M, Sarkar G, Hickman SJ, Downes SM, Jayawant S, Yu-Wai-Man P, Taylor RW, Poulton J (2016) The m.13051G>A mitochondrial DNA mutation results in variable neurology and activated mitophagy. Neurology 86:1921\u20131923","journal-title":"Neurology"},{"key":"4444_CR25","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1093\/brain\/awt343","volume":"137","author":"C Giordano","year":"2014","unstructured":"Giordano C, Iommarini L, Giordano L, Maresca A, Pisano A, Valentino ML, Caporali L, Liguori R, Deceglie S, Roberti M, Fanelli F, Fracasso F, Ross-Cisneros FN, D'Adamo P, Hudson G, Pyle A, Yu-Wai-Man P, Chinnery PF, Zeviani M, Salomao SR, Berezovsky A, Belfort R Jr, Ventura DF, Moraes M, Moraes Filho M, Barboni P, Sadun F, De Negri A, Sadun AA, Tancredi A, Mancini M, d'Amati G, Loguercio Polosa P, Cantatore P, Carelli V (2014) Efficient mitochondrial biogenesis drives incomplete penetrance in Leber\u2019s hereditary optic neuropathy. Brain 137:335\u2013353","journal-title":"Brain"},{"key":"4444_CR26","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.preteyeres.2003.10.003","volume":"23","author":"V Carelli","year":"2004","unstructured":"Carelli V, Ross-Cisneros FN, Sadun AA (2004) Mitochondrial dysfunction as a cause of optic neuropathies. Prog Retin Eye Res 23:53\u201389","journal-title":"Prog Retin Eye Res"},{"key":"4444_CR27","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1021\/tx970136j","volume":"11","author":"A Mordente","year":"1998","unstructured":"Mordente A, Martorana GE, Minotti G, Giardina B (1998) Antioxidant properties of 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone (idebenone). Chem Res Toxicol 11:54\u201363","journal-title":"Chem Res Toxicol"},{"key":"4444_CR28","doi-asserted-by":"publisher","first-page":"e17963","DOI":"10.1371\/journal.pone.0017963","volume":"6","author":"RH Haefeli","year":"2011","unstructured":"Haefeli RH, Erb M, Gemperli AC, Robay D, Courdier Fruh I, Anklin C, Dallmann R, Gueven N (2011) NQO1-dependent redox cycling of idebenone: effects on cellular redox potential and energy levels. PLoS One 6:e17963","journal-title":"PLoS One"},{"key":"4444_CR29","doi-asserted-by":"publisher","first-page":"e36153","DOI":"10.1371\/journal.pone.0036153","volume":"7","author":"M Erb","year":"2012","unstructured":"Erb M, Hoffmann-Enger B, Deppe H, Soeberdt M, Haefeli RH, Rummey C, Feurer A, Gueven N (2012) Features of Idebenone and related short-chain Quinones that rescue ATP levels under conditions of impaired mitochondrial complex I. PLoS One 7:e36153","journal-title":"PLoS One"},{"key":"4444_CR30","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.mito.2017.01.004","volume":"36","author":"P Yu-Wai-Man","year":"2017","unstructured":"Yu-Wai-Man P, Soiferman D, Moore DG, Burt\u00e9 F, Saada A (2017) Evaluating the therapeutic potential of idebenone and related quinone analogues in Leber hereditary optic neuropathy. Mitochondrion 36:36\u201342","journal-title":"Mitochondrion"},{"key":"4444_CR31","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.neuropharm.2018.07.001","volume":"139","author":"M Caillaud","year":"2018","unstructured":"Caillaud M, Chantemargue B, Richard L, Vignaud L, Favreau F, Faye PA, Vignoles P, Sturtz F, Trouillas P, Vallat JM, Desmouli\u00e8re A, Billet F (2018) Local low dose curcumin treatment improves functional recovery and remyelination in a rat model of sciatic nerve crush through inhibition of oxidative stress. Neuropharmacology 139:98\u2013116","journal-title":"Neuropharmacology"},{"key":"4444_CR32","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.1007\/s12035-016-9891-5","volume":"54","author":"HR Ghaiad","year":"2017","unstructured":"Ghaiad HR, Nooh MM, El-Sawalhi MM, Shaheen AA (2017) Resveratrol promotes remyelination in cuprizone model of multiple sclerosis: biochemical and histological study. Mol Neurobiol 54:3219\u20133229","journal-title":"Mol Neurobiol"},{"key":"4444_CR33","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.biopha.2018.02.125","volume":"101","author":"R Naeimi","year":"2018","unstructured":"Naeimi R, Baradaran S, Ashrafpour M, Moghadamnia AA, Ghasemi-Kasman M (2018) Querectin improves myelin repair of optic chiasm in lyolecithin-induced focal demyelination model. Biomed Pharmacother 101:485\u2013493","journal-title":"Biomed Pharmacother"},{"key":"4444_CR34","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.lfs.2018.07.001","volume":"207","author":"S Baradaran","year":"2018","unstructured":"Baradaran S, Hajizadeh Moghaddam A, Ghasemi-Kasman M (2018) Hesperetin reduces myelin damage and ameliorates glial activation in lysolecithin-induced focal demyelination model of rat optic chiasm. Life Sci 207:471\u2013479","journal-title":"Life Sci"},{"key":"4444_CR35","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1136\/bjo.84.5.534","volume":"84","author":"M Nakamura","year":"2000","unstructured":"Nakamura M, Yamamoto M (2000) Variable pattern of visual recovery of Leber's hereditary optic neuropathy. Br J Ophthalmol 84:534\u2013535","journal-title":"Br J Ophthalmol"},{"key":"4444_CR36","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1186\/s12886-017-0583-3","volume":"17","author":"Y Mashima","year":"2017","unstructured":"Mashima Y, Kigasawa K, Shinoda K, Wakakura M, Oguchi Y (2017) Visual prognosis better in eyes with less severe reduction of visual acuity one year after onset of Leber hereditary optic neuropathy caused by the 11,778 mutation. BMC Ophthalmol 17:192","journal-title":"BMC Ophthalmol"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-019-04444-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00417-019-04444-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-019-04444-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T23:12:03Z","timestamp":1599001923000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00417-019-04444-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,3]]},"references-count":36,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["4444"],"URL":"https:\/\/doi.org\/10.1007\/s00417-019-04444-6","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,3]]},"assertion":[{"value":"17 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"B. Pemp has received travel reimbursements and speaker honoraria from Santhera Pharmaceuticals. K. Kircher and A. Reitner declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the ethics committee of the Medical University of Vienna and with the 1964 Helsinki declaration and its later amendments or comparable standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}